Cross-Protection

How it works

Comparisons

Highlighted claims

• N. gonorrhoeae encodes homologues of fHbp, NHBA, GNA2091, and GNA1030, but not NadA. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• OMV surface proteins from the NmB strain used in 4CMenB share a mean sequence conservation of 91.0% with gonococcal homologues. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• Human 4CMenB vaccination has demonstrated IgG responses against gonococcal outer-membrane proteins and serum bactericidal activity against N. gonorrhoeae strains. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• NmB is closely related to N. gonorrhoeae, supporting the plausibility of vaccine cross-protection. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• The gonococcal fHbp homologue appears intracellular, which may limit its contribution to cross-protection. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol